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ABSTRACT α1-Antitrypsin (α1-AT) deficiency is a risk factor for emphysema due to tissue damage by
serine proteases. Neutrophil elastase (NE) has long been considered the enzyme responsible. However,
proteinase 3 (PR3) also produces the pathological features of chronic obstructive pulmonary disease
(COPD), is present in the same granules in the neutrophil and is inhibited after NE. We developed a
specific footprint assay for PR3 activity and assessed its relationship to an NE footprint in α1-AT
deficiency.
An ELISA was developed for the specific PR3 fibrinogen cleavage site Aα-Val541. Levels were measured
in plasma from 239 PiZZ patients, 94 PiSZ patients, 53 nondeficient healthy smokers and 78 individuals
with usual COPD. Subjects underwent extensive demographic characterisation including full lung function
and lung computed tomography scanning.
Aα-Val541 was greater than the NE footprint in all cohorts, consistent with differential activity. Values
were highest in the PiZZ α1-AT-deficient patients and correlated with the NE marker Aα-Val
360, but were
∼17 times higher than for the NE footprint, consistent with a greater potential contribution to lung
damage. Aα-Val541 was related cross-sectionally to the severity of lung disease (forced expiratory volume
in 1 s % pred: rs=−0.284; p<0.001) and was sensitive to augmentation therapy, falling from 287.2 to
48.6 nM (p<0.001).
An in vivo plasma footprint of PR3 activity is present in greater quantities than an NE footprint in
patients with α1-AT deficiency, is sensitive to augmentation therapy and represents a likely biomarker for
dose-ranging studies.
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This novel assay provides evidence of proteinase 3 activity in α1-antitrypsin deficiency,
suggesting it may play a significant role in lung tissue damage and act as a specific biomarker
for augmentation therapy http://bit.ly/32dnx66
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Introduction
Proteolytic enzymes have long been implicated in the pathophysiology of chronic obstructive pulmonary
disease (COPD), especially in emphysema-dominant phenotypes. This concept originated with the
observation that α1-antitrypsin (α1-AT)-deficient individuals were particularly susceptible to the
development of emphysema [1]. α1-AT is a major inhibitor of neutrophil serine proteinases and animal
studies identified the central role of neutrophil elastase (NE) as the mediator of pathological changes
typical of COPD [2]. However, two other serine proteinases are co-localised in the azurophil granule with
NE, i.e. proteinase 3 (PR3) and cathepsin G, and are released into the pericellular environment with NE
following neutrophil activation. PR3 in particular can produce the same bronchial and emphysematous
changes as NE in animal models [3]. In addition, PR3 has also been implicated in cellular apoptosis,
which is thought to be another key process in the development of emphysema [4].
PR3 is stored as a proenzyme in the azurophil granule with NE, although the quantity is uncertain. Direct
immunostaining indicates increased total PR3 [5] whereas indirect assays by subtraction indicate reduced
activity concentrations [6] compared with NE. However, PR3 has a lower association rate constant with
α1-AT [7], suggesting it is likely to have more prolonged activity than NE before inactivation leading to
α1-AT/enzyme complex formation, as demonstrated by mathematical modelling [7]. Indeed, studies of
airways secretions in both α1-AT-deficient and nondeficient COPD indicate that uninhibited PR3 activity
is more likely to be present than uninhibited NE activity [8], supporting a more persistent role for PR3 in
the development of COPD and emphysema.
The development of emphysema is believed to relate mainly to connective tissue destruction
(predominantly elastin) in the lung interstitium. This provides a major impediment to assessing the
focused local interstitial activity of these enzymes because of access to the site of action and rapid
inhibition in situ that is not necessarily reflected in sputum studies.
As neutrophils migrate into the lung they are accompanied by plasma proteins including fibrinogen [9];
thus, we hypothesised that specific fibrinogen cleavage products would be generated at the point of
neutrophil activation in the interstitium, acting as a footprint of local enzyme activity and be detectable
(although likely at a lower level) in the plasma through lymph recirculation. Indeed, an NE footprint
(Aα-Val360) is raised in α1-AT deficiency, is reduced by α1-AT augmentation therapy and increases during
exacerbations, providing validation for this concept [10, 11].
The purpose of the present study was to develop a specific “footprint” assay for PR3 also based on
fibrinogen cleavage that would be measurable in plasma, and to assess its relationship to respiratory
dysfunction in α1-AT deficiency and sensitivity to change during augmentation therapy.
Materials and methods
Aa-Val541 assay
The methodology and validation of the assay is covered in the supplementary material. Cleavage of
fibrinogen with PR3 produced several fragments, one of which was detected in plasma from
α1-AT-deficient patients and digested to obtain the carboxyl-terminal amino acid sequence ending at
position 541.
Briefly, we generated antiserum that recognised the free carboxyl amino acid of Aα-Val541 (normally
linked with Ser542). The peptide COM536LGEFV541 was conjugated to thyroglobulin using the
cross-linking reagent Sulfo-MBS (m-maleimidobenzoyl-N-hydroxysulfosuccinimide ester) (figure 1) and
rabbits were immunised with the conjugate. The subsequent antiserum was harvested and an indirect
ELISA developed as described in the supplementary material.
H2N-Cys-Orn-Met-Leu-Gly-Glu-Phe-Val541-COOH
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FIGURE 1 The peptide conjugate. 6-mer peptide MLGEFV with an additional cysteine (Cys) and unnatural
ornithine (Orn) at the amino terminus (COM536LGEFV541). Coupled to bovine thyroglobulin using Sulfo-MBS.
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Once the assay was established, the antiserum was validated in several ways. 1) Carboxyl-terminal
extensions (1-mer and 6-mer) were added to COMLGEFV and a further peptide had the terminal valine
removed, and these were used to confirm antibody specificity. 2) The NE-specific peptide also with a
terminal valine (CJTSESSV from the Aα-Val360 assay) was tested to ensure no cross-reactivity. 3) Various
concentrations of PR3-cleaved, NE-cleaved or uncleaved fibrinogen were measured to determine the degree
of recognition of the peptides generated in these preparations (all human plasma samples contain some of
the enzyme-specific peptides as a result of physiological activity of neutrophils in health). The results of
these validation experiments are shown in supplementary figures E4–E7.
Aa-Val360 assay
The relationship between Aα-Val541 and the NE-specific cleavage product Aα-Val360 was determined using
plasma samples from α1-AT-deficient patients, COPD patients and healthy smoking controls. The full
methodology for the Aα-Val360 assay has been described previously [10].
Study subjects
The initial cohort for this study consisted of 180 homozygous Z allele (PiZZ) patients with severe α1-AT
deficiency enrolled as part of the UK National Institute of Health Research (NIHR) Rare Diseases
Translational Research Collaboration. The subjects (all ex-smokers for >12 months or never-smokers) were
recruited from six UK sites (Birmingham, Cambridge, Leicester, Nottingham, Royal Brompton (London)
and Southampton) and gave written informed consent (South Birmingham Research Ethics Committee
LREC 3359).
Subjects underwent extensive demographic characterisation including full, post-bronchodilator lung
function testing and densitometric analysis of high-resolution chest computed tomography at full
inspiration using an established analysis programme (Pulmo CMS; Medis Specials, Leiden, The
Netherlands). The severity of airflow obstruction varied from none to very severe as quantified by Global
Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease (GOLD)
staging criteria [12]. Plasma was taken and stored at −80°C until analysed.
Plasma was also analysed from two other patient groups in the UK α1-AT-deficient registry (ADAPT)
programme described elsewhere [13]. A cohort of 94 individuals with the PiSZ genotype (α1-AT levels
∼40% of normal), 59 PiZZ α1-AT-deficient patients with “early” disease defined as those without
spirometric evidence of COPD (forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) >0.7)
or with GOLD Stage I (mild) obstruction collected as part of an Alpha 1 Foundation cohort of early/mild
disease and 78 usual COPD patients, including both current (n=30) and ex-smokers (n=48), without
α1-AT deficiency (FEV1/FVC <0.7 and FEV1 <80% predicted) recruited through the NIHR-funded
Clinical Research Facility (Queen Elizabeth Hospital Birmingham, Birmingham, UK). Finally, 53 healthy
smokers (FEV1/FVC >0.7, age 41–79 years) were studied to determine a healthy range for Aα-Val541.
Samples from 39 α1-AT-deficient patients were repeated after 12–24 months while still clinically stable to
assess consistency of the result. Plasma was also assessed for 21 α1-AT-deficient patients before (baseline)
and at 6 months during augmentation therapy with α1-AT, and for 15 patients before and during placebo
therapy, as described previously [10] to determine the effect of replenishment. No patient in any group
had experienced an acute exacerbation in the 6 weeks prior to assessment.
Statistical analysis
Statistical analysis was performed using SPSS Statistics version 22.0 (IBM, Armonk, NY, USA). Normality
was tested using the Shapiro–Wilk test and statistical significance between groups was taken as p<0.05.
Aα-Val541 and Aα-Val360 were not normally distributed, and therefore expressed as median and
interquartile range (IQR) for group data, and correlations were performed using Spearman’s rs with
log-transformed data. The Wilcoxon signed-rank test was used to determine any differences in paired
samples (i.e. Aα-Val541 stability over time or before/after augmentation therapy) and the Mann–Whitney
test was used to determine any differences between groups. Where multiple comparisons were made, a
Holm–Bonferroni correction was applied.
Results
The results of the assay development and validation are described in detail in the supplementary material.
The inter- and intra-assay coefficients of variation were 23.6% and 8.5%, respectively.
The demographic features of the α1-AT-deficient patients, nondeficient COPD patients and healthy
control subjects are summarised in table 1. Lung function was corrected for age, sex, ethnicity and height
using the Global Lung Function Initiative 2012 equations [14]. Lung densitometry was available for 191 of
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the 239 PiZZ subjects and mean results are also shown using accepted parameters to quantify emphysema
as described previously [15].
Aa-Val541 concentrations in health, COPD and a1-AT deficiency
The Aα-Val541 concentrations showed a wide range for all cohorts. The median (IQR) concentration of
Aα-Val541 was 270.0 (158.9–440.6) nM in the PiZZ α1-AT-deficient cohort but was lower in PiSZ patients
(58.8 (39.4–87.1) nM; p<0.001) and lower still for nondeficient COPD patients (20.0 (13.3–32.1) nM;
p<0.001) and healthy smokers (27.6 (15.0–40.0 nM); p<0.001). Individual results are shown for each of
these patient groups in figure 2.
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FIGURE 2 Individual Aα-Val541 concentrations for healthy subjects, individuals with chronic obstructive
pulmonary disease, and the PiSZ and PiZZ α1-antitrypsin-deficient patient cohorts (p<0.001 between all
groups except healthy smokers versus COPD (p=0.112), tested by the Mann–Whitney U-test). Each point
represents the result for a single patient. The median and interquartile range are shown as horizontal lines.
TABLE 1 Demographic features of healthy individuals, chronic obstructive pulmonary disease
(COPD) patients, α1-antitrypsin-deficient subjects with the PiSZ genotype and the combined
PiZZ cohort
Healthy COPD# PiSZ PiZZ¶
Subjects 53 78 94 239
Age years 61.5±10.5 66.0±9.4 52.4±15.1 57.2±11.2
Sex
Male 28 (52.8) 50 (64.1) 50 (55.6) 117 (49.0)
Female 25 (47.2) 28 (35.9) 40 (44.4) 122 (51.0)
FEV1 % pred 109.97±15.76 54.49±22.46 90.00±32.66 66.21±32.02
FEV1/FVC % 76.93±6.28 47.59±15.68 63.28±21.12 48.44±20.51
KCO % pred 97.60±17.55 64.89±19.87 85.62±27.75 63.52±18.92
Perc15 HU NA NA NA −950.79±26.73
HU910 % NA NA NA 44.40±18.29
HU950 % NA NA NA 19.90±14.67
Data are presented as n, mean±SD or n (%). FEV1: forced expiratory volume in 1 s; FVC: forced vital
capacity; KCO: transfer coefficient of the lung for carbon monoxide; Perc15: density below which the lowest
15% of voxels occurs; HU910 and HU950: proportion of voxels with density below these Hounsfield unit
thresholds. Full analysis of computed tomography densitometry (used widely in observational and clinical
trials) was available for 191 patients and this dataset is summarised for the PiZZ α1-AT-deficient patients
only. #: FEV1 n=77, FEV1/FVC n=76 and KCO n=28; ¶: FEV1 n=237, FEV1/FVC n=238 and KCO n=233.
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Effect of smoking
None of the α1-AT-deficient patients were current smokers. However, the usual COPD group consisted of
30 current and 48 ex-smokers. The median (IQR) Aα-Val541 was lower in ex-smokers (17.5
(11.8–30.0) nM) compared with current COPD smokers (22.6 (15.2–35.3) nM; p=0.05). In addition, it was
also lower than in healthy smokers (27.6 (15.0–40.0) nM; p=0.036). There was no difference between
current COPD smokers and healthy smokers (p=0.765).
Relationship to baseline demographic data
The relationship of Aα-Val541 to baseline demographics of the PiZZ cohort are summarised in table 2.
There were significant correlations between Aα-Val541 and airflow obstruction, gas transfer and lung
densitometry (where this was available) with the exception of the percentage of voxels less than −910 HU.
No correlations were seen with baseline data from the other three groups. Individual Aα-Val360 values
showed no significant correlations with baseline demographics.
Relationship to the NE footprint marker Aa-Val360
The PR3 activity marker showed a positive correlation with the previously validated NE activity footprint
marker Aα-Val360 (rs=0.266; p<0.001) in the PiZZ cohort (figure 3). The intercept of this relationship
using linear regression was log 1.86, suggesting that PR3 activity would remain ∼72 nM after the NE had
been completely inhibited. A positive correlation was also seen in the COPD cohort (rs=0.232; p=0.021)
with the intercept using linear regression (log 0.70), suggesting that PR3 activity would be minimal
(∼5 nM) if NE footprint activity was zero. No significant correlation was observed between the two
markers (Aα-Val360 and Aα-Val541) in the PiSZ (rs=0.074; p=0.242) or the healthy smoking (rs=0.079;
p=0.289) groups.
Ratio of the two footprints
Values for the Aα-Val360 footprint were lower than for the Aα-Val541 footprint in each patient group. The
median (IQR) Aα-Val360 value in healthy smokers was 9.2 (7.3–11.5) nM and this was lower than for
nondeficient COPD patients (11.7 (9.1–13.2) nM; p<0.001), which in turn was lower than for PiSZ
patients (13.5 (11.0–18.2 nM); p<0.001). However, the data for PiSZ patients were similar to the data for
PiZZ patients (14.5 (11.7–18.8) nM; p=0.116).
The Aα-Val541/Aα-Val360 ratio also showed wide variation with a median (IQR) of 2.6 (1.8–4.4) for
healthy smokers and 1.9 (1.4–2.8) for nondeficient COPD patients. In the COPD group the ratio was
higher for current smokers than ex-smokers (2.0 (1.7–3.1) and 1.6 (1.1–2.6), respectively; p=0.008). Ratios
were higher (p=0.0067) for PiSZ subjects (4.1 (2.4–6.8)) compared with healthy smokers and more so
(p<0.001) for PiZZ subjects (17.1 (10.0–29.3)). The data for individual patients are shown in figure 4.
Stability
Plasma was collected from 39 α1-AT-deficient (PiZZ) patients at baseline and 12–24 months later to assess
Aα-Val541 stability. The median (IQR) concentration at baseline (281.4 (168.4–332.9) nM) was not
significantly different to the second sample (215.2 (135.6–352.9) nM), indicating relative stability over at
TABLE 2 Correlation coefficients and significance values for Aα-Val541 together with the
number of patients assessed with complete data for analysis from the combined PiZZ cohort
Clinical Patients n Correlation coefficient rs p-value
Age 239 0.059 0.183
FEV1 % pred 237 −0.284 <0.001#
FEV1/FVC 238 −0.247 <0.001#
KCO % pred 233 −0.124 0.030#
Perc15 HU 191 −0.198 0.003#
HU910 % 191 0.115 0.057
HU950 % 191 0.182 0.006#
FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; KCO: transfer coefficient of the lung for
carbon monoxide; Perc15: density below which the lowest 15% of voxels occurs; HU910 and HU950:
proportion of voxels with density below these Hounsfield unit thresholds. Lung densitometric analysis
assessing emphysema is shown as Perc15, HU910 and HU950. #: p-values which remained statistically
significant following Holm–Bonferroni correction for multiple comparisons.
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least a year as seen for Aα-Val360 [10]. In addition, unthawed samples from previous clinical trials stored
for longer periods provided comparable group data to that seen with fresh samples, suggesting even
long-term storage retains stability.
Effect of augmentation in a1-AT-deficient subjects
Previously we showed that augmentation therapy with α1-AT (prolastin 60 mg·kg
−1 weekly) in α1-AT
deficiency as part of the EXACTLE trial led to a small but significant reduction in the NE footprint,
suggesting better local control of NE activity [10]. We assessed the remaining samples from 36 patients in
this trial (all measured at baseline: 21 on α1-AT treatment and 15 receiving placebo for 6 months) to
assess the effect of augmentation on the PR3 footprint. Median (IQR) Aα-Val541 values prior to therapy
(287.2 (154.0–375.4) nM) fell on therapy (48.6 (37.7–71.8) nM; p<0.001), indicating marked suppression
of local PR3 activity, although the data still remained elevated compared with healthy controls (p<0.001)
and nondeficient COPD patients (p<0.001), but comparable to the data for PiSZ subjects. No difference
FIGURE 3 Spearman’s correlation
(rs=0.266; p<0.001) between log
values for Aα-Val541 and Aα-Val360
in 239 patients from the PiZZ
α1-antitrypsin-deficient cohort.
Each point represents a sample
from an individual patient.
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FIGURE 4 Comparison of the ratio of Aα-Val541 and Aα-Val360 levels in the PiSZ and PiZZ
α1-antitrypsin-deficient patients, nondeficient chronic obstructive pulmonary disease (COPD) patients, and
healthy smoking controls. The median and interquartile range are shown as solid lines. The median
Aα-Val541/Aα-Val360 ratio was 2.6 for the healthy group, 1.9 for the COPD group, 4.1 for the PiSZ cohort and
17.1 for the PiZZ cohort. The ratio for healthy individuals was significantly lower than for the PiSZ cohort
(p<0.01) and the PiZZ cohort (p<0.001), but significantly higher than the COPD group (p<0.01), tested by the
Mann–Whitney U-test.
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(p=0.363) was seen in patients receiving placebo (median Aα-Val541 concentration 340.2 (199.0–552.9) nM
at baseline and 281.8 (257.5–596.7) nM after 6 months).
Discussion
This article describes a unique epitope of fibrinogen cleavage providing a footprint to identify and track
neutrophil PR3 activity in vivo. In healthy individuals this footprint is almost three times greater than the
equivalent NE footprint and would be consistent with the greater amount of PR3 stored in the azurophil
granule reported previously [5]. Both enzymes would be released with neutrophil degranulation, leading to
an area of obligate enzyme activity until diffusion dilutes each enzyme to equal that of the surrounding
α1-AT [16]. Our data support this concept. The data are also consistent with the greater likelihood of
detecting PR3 activity compared with NE activity in the airways of patients with nondeficient COPD [8]
where the prevalent lung α1-AT level is further reduced due to restricted diffusion from plasma by the
tight epithelial cell junctions [17] and the lack of a significant local inhibitor of PR3 [7].
There are several factors that likely have a greater influence on the in vivo activity of PR3 in patients with
α1-AT deficiency. These include the low concentration of α1-AT, the higher PR3 concentration in the
neutrophil, the reduced association rate constant compared with NE [7] as well as the lack of local lung
inhibitors [8]. The net result is reflected in a ∼17-fold greater PR3 footprint than that of NE. In addition,
although the PR3 and NE footprints correlate, the data do not extrapolate to the origin, suggesting
significant PR3 activity would persist even after NE had been inhibited in α1-AT deficiency due to the
reasons outlined earlier.
Although both proteinase footprints correlate, only the PR3 footprint related cross-sectionally to lung
function and lung densitometry in the PiZZ cohort. The data suggest, at least superficially, that the PR3
footprint would be a better biomarker for the study of lung disease in α1-AT deficiency. However, the
relationship between lung disease and biomarkers is complex [18]. Correlations raise the issue of cause
and effect, and in our previous study in PiZZ patients the NE footprint (although stable) did not relate to
subsequent progression in those with established COPD (i.e. the activity of the disease), supporting the
concept that it reflected, at least in part, the effect of COPD rather than the cause [19]. This was consolidated
further by association of the NE footprint with subsequent progression only in α1-AT-deficient patients
without COPD, suggesting that other factors play a role in established COPD [10].
In the nondeficient COPD cohort studied here, the PR3 footprint was lower than for both the PiZZ and
PiSZ subgroups. This would be expected due to the normal α1-AT levels in nondeficient patients and was
not different to that in healthy smokers. However, only a proportion of the COPD patients remained
currently smoking. The ex-smokers had a lower median PR3 footprint, suggesting it is, at least in part, a
smoking-related signal in nondeficient COPD.
The PR3 footprint (like the NE footprint) in α1-AT deficiency (although highly variable between
individuals) is stable, suggesting it has reached equilibrium and therefore it remains possible that
pre-inhibition PR3 activity is a major mediator of damage in established COPD related to α1-AT
deficiency. Interpretation of this baseline relationship is, however, further complicated by the fact that
many α1-AT-deficient patients studied here were ex-smokers, which would likely have had an amplifying
effect on current lung status prior to PR3 footprint assessment. Further studies will therefore be required
to determine future disease progression in α1-AT-deficient never- or ex-smokers and any relationship to
baseline PR3 footprint activity.
Augmentation therapy with human α1-AT leads to a major reduction in the PR3 footprint (as seen
previously for the lower NE footprint) [10] almost, although not quite, back to normal, indicating that this
treatment limits the detectable in vivo activity of both enzymes (prior to inhibition and complex
formation with α1-AT), but suggests that a higher dose may be required to normalise PR3 activity. The
data support, at least in part, the benefits of such therapy on emphysema progression in α1-AT deficiency
[20–22] and a role for Aα-Val541 as a biomarker for this treatment effect.
The results for the PiSZ patients are worthy of further comment. There remains uncertainty about the
susceptibility of this α1-AT genotype to developing COPD and hence any role for augmentation therapy.
The NE footprint in these patients was slightly raised compared with the healthy controls, as was the PR3
footprint and the NE/PR3 footprint ratio. However, the NE footprint in PiSZ patients was similar to that
seen in PiZZ patients where lung disease severity and progression are greater This also suggests that NE
may be less important in lung elastin destruction than PR3 in this patient group, and that the lower than
normal α1-AT level and decreased association rate constant of PiZZ α1-AT for PR3 [7] result in a mild
imbalance of PR3 activity compared with usual nondeficient COPD (indicated by the ratio of the two
footprints) and may be a physiological mediator of increased tissue damage, and hence a target for
treatment in PiSZ subjects. Clearly, further exploration of this issue is indicated.
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The current study has both strengths and some weaknesses. The validation of the Aα-Val541 assay
confirms its specificity for the cleavage peptide and suggests the predominance of a PR3 signal in all
cohorts consistent with its greater concentration than NE in the azurophil granule. In addition, the even
greater PR3 footprint signal in α1-AT deficiency confirms the potential importance of this enzyme with
low concentrations of α1-AT compounded by its lower association rate constant and the lack of another
local lung PR3 inhibitor [7].
However, there is some controversy concerning the amount of PR3 in the azurophil granule (see
Introduction); if the absolute amount of PR3 in the neutrophil is similar to or lower than NE, the
difference seen in the footprint assays requires consideration for other possibilities. Both enzymes are
promiscuous and can potentially have multiple cleavage sites. For this reason our initial digest and plasma
analyses identified a fibrinogen cleavage product produced by PR3 present in the plasma of
α1-AT-deficient subjects and not generated by NE. Carboxyl-terminal sequencing was consistent with a
PR3 cleavage site exposing a neo-epitope, and our subsequent analyses indicated no or only very weak
binding by NE-cleaved fibrinogen and no cross-reactivity with our NE-specific cleavage sequence (the
Aα-Val360 peptide).
It remains possible that the respective half-lives of these two fibrinogen cleavage products differ, producing
some cross-sectional differences in the quantity of both, although this should not vary with α1-AT
genotype producing the major differences observed here. In addition, augmentation brings these two
signals together, suggesting the neo-epitopes generated are predominantly related to activity rather than
half-life. Finally, compared with NE, PR3 activity may be preferentially located at the neutrophil
membrane where it is less susceptible to inhibition by α1-AT [5], facilitating its local pericellular activity
and hence fibrinogen cleavage. These issues can only be addressed by complex in vitro competition assays,
but would require simultaneous pharmacokinetics analysis of patient samples from those receiving both
α1-AT augmentation and the inclusion of future specific and effective anti-NE or -PR3 therapies.
However, whatever the reason, we have studied several independent cohorts including both a severe
α1-AT-deficient group (PiZZ), a mild α1-AT-deficient group (PiSZ) and a normal α1-AT COPD group to
consolidate the relationship of the marker to α1-AT deficiency and its severity in the stable state,
indicating clear differences in the ratio of the two footprints. Whether the PR3 marker predicts future
progression of disease in α1-AT deficiency is important, and this now requires longitudinal monitoring of
disease progression in both the presence and absence of α1-AT augmentation therapy. This has important
implications for the management of α1-AT deficiency as, although α1-AT will inhibit both PR3 and NE,
the pursuit and development of specific small-molecule inhibitors of NE that do not have broad activity to
control both serine proteinases may be inappropriate or only provide partial protection, especially in
α1-AT deficiency. However, inhibiting NE by an alternative route may paradoxically release enough
endogenous α1-AT to provide extra PR3 cover. Clearly, such studies need to be undertaken and will
provide important insights into neutrophil proteinase biology. The PR3 signal is high and certainly
sensitive to augmentation, and may therefore prove essential as a treatment biomarker in future proteinase
therapeutic strategies, including dose-ranging studies.
The fibrinogen footprint of PR3 activity is also likely to be an indirect marker of elastin degradation
considered central to the pathophysiology of emphysema. Since our results were generated, a recent article
using a similar methodology to measure a PR3-specific elastin cleavage product in healthy controls and a
COPD cohort indicates similar increased PR3 compared with an NE cleavage product to that seen here
[23]. Direct comparison of both assays should, however, be undertaken in a single α1-AT-deficient cohort
for final confirmation.
We describe a unique in vivo footprint of PR3 activity that is present in greater quantities than an NE
footprint in subjects with normal α1-AT, but especially in the presence of α1-AT deficiency. The data
suggest that PR3 may play a greater role in lung damage than previously thought and is sensitive to
antiprotease therapy. As such, it may provide a critical role as a biomarker for dose ranging of antiprotease
therapy. The specificity of the PR3 assay suggests it may also be useful in the assessment of other
PR3-dependent diseases such as autoimmune vasculitis.
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